Pharma's pipeline problems, coupled with the trend toward acquisition, are giving biotechs more leverage in licensing discussions.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Related links
Related links
Related links in Nature Research
A reprise for collaborative financing in biotech
Pipeline cherrypicking deal yields lucrative return
Are small biotechs still underselling themselves?
Web links
Rights and permissions
About this article
Cite this article
Moran, N. Licensing deals morph to acquisitions in seller's market. Nat Biotechnol 25, 609–610 (2007). https://doi.org/10.1038/nbt0607-609
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0607-609